Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology Pages 417-418

Press Release

Press Release From
National Cancer Institute
Office of Cancer Communication
1 p.m. EDT Monday, April 6, 1998

Breast Cancer Prevention Trial Shows Major Benefit, Some Risk

Six years after its inception, the Breast Cancer Prevention Trial (BCPT) shows a 45 per cent reduction in breast cancer incidence among the high-risk participants who took tamoxifen (Nolvadex[), a drug used for the past two decades to treat breast cancer.

As a result, investigators released the initial study results about 14 months earlier than expected. They also notified the 13,388 women participants of the findings, so those women who had been taking the placebo could consider starting tamoxifen therapy after consulting with their personal physicians. Participants will continue to be followed by the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Pittsburgh-based research network that conducted the trial with support from the National Cancer Institute (NCI).

In this trial, healthy women assigned to take tamoxifen developed 85 cases of invasive breast . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?